Ipsen’s Cabometyx Receives Health Canada’s Approval for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults

 Ipsen’s Cabometyx Receives Health Canada’s Approval for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults

Ipsen’s Cabometyx Receives Health Canada’s Approval for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults

Shots:

  • Approval of Cabometyx (cabozantinib) is based on results of the P-III METEOR trial assessing Cabometyx vs everolimus for advanced (RCC) previously received vascular endothelial growth factor (VEGF) targeted therapy, demonstrated significant and clinical improvement in OR, PFS, ORR
  • Cabometyx received priority review status from Health Canada further assisted its approval. In 2017, the US FDA granted orphan drug designation to cabozantinib for the treatment of advanced HCC
  • In 2016, Ipsen received exclusive rights from Exelixis, for commercialization and development of cabozantinib outside of the US and Japan

Click here to read full press release/ article | Ref: Exelixis | Image: Pharmaceutical daily news

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post